Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Deuterium
What happens when patents do not reward R&D?

One of the common refrains from the pro-patent drug chorus is that patents are necessary to protect and incentivize expensive research and development by pharmaceutical companies.  While that may be true in some cases, there are examples where it is clearly not.  One current example includes deuterated analogs for ruxolitinib.  One company researched which deuterated analogs among thousands of possibilities might be useful, whereas a different company cornered the market on all deuterated analogs based upon two sentences in patent disclosure years ago.  Guess who wins.

Read More